First orders for dental and nerve products
Orthocell has now received first purchase orders for our flagship collagen medical device products Striate+™ and Remplir, via our valued distribution partners.
This commercial milestone follows Orthocell’s recent exclusive global licence and distribution deal with BioHorizons Implant Systems Inc. (BioHorizons) for Striate+™, and exclusive Australian distribution agreement with Device Technologies (DVT) for Remplir™ – both defining achievements for our growing Company.
Click here to view today’s ASX release.